Iván J Núñez-Gil1, Antonio Fernández-Ortiz2, Charbel Maroud Eid3, Jia Huang4, Rodolfo Romero5, Victor Manuel Becerra-Muñoz6, Aitor Uribarri7, Gisela Feltes8, Daniela Trabatoni9, Inmaculada Fernandez-Rozas10, Maria C Viana-Llamas11, Martino Pepe12, Enrico Cerrato13, Maurizio Bertaina14, Thamar Capel Astrua15, Emilio Alfonso16, Alex F Castro-Mejía17, Sergio Raposeiras-Roubin18, Fabrizio D'Ascenzo19, Carolina Espejo Paeres20, Jaime Signes-Costa21, Alfredo Bardaji22, Cristina Fernandez-Pérez2, Francisco Marin23, Oscar Fabregat-Andres24, Ibrahim Akin25, Vicente Estrada2, Carlos Macaya2. 1. Hospital Clinico San Carlos, Prof Martin Lagos, sn, 28040 Madrid, Spain. ibnsky@yahoo.es. 2. Hospital Clinico San Carlos, Prof Martin Lagos, sn, 28040 Madrid, Spain. 3. H La Paz, Madrid, Spain. 4. The Second People's Hospital of Shenzhen, Shenzhen, China. 5. Hospital Universitario Getafe, Madrid, Spain. 6. Unidad de Gestión Clínica Área del Corazón, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga (UMA), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Málaga, Spain. 7. Hospital Clínico Universitario de Valladolid, Valladolid, Spain. 8. Hospital Nuestra Señora de América. 9. Centro Cardiologico Monzino, IRCCS, Milano, Italy. 10. Hospital Severo Ochoa, Leganés, Spain. 11. Hospital Universitario Guadalajara, Guadalajara, Spain. 12. Azienda ospedaliero-universitaria consorziale policlinico di Bari. 13. San Luigi Gonzaga University Hospital, Rivoli, Turin. Italy. 14. Martini Hospital,via Tofane, Turin. Italy. 15. Hospital Virgen del Mar, Madrid, Spain. 16. Instituto de Cardiología y Cirugía Cardiovascular, Havana, Cuba. 17. Hospital General del norte de Guayaquil IESS Los Ceibos. 18. University Hospital Álvaro Cunqueiro, Vigo. Spain. 19. San Giovanni Battista. 20. H Principe Asturias, Alcalá de Henares, Spain. 21. Hospital Clínico Universitario, Incliva, Universidad de Valencia, Valencia, Spain. 22. University Hospital Joan XXIII. Tarragona. Spain. 23. Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain. 24. Hospital IMED, Valencia, Spain. 25. First Department of Medicine, Medical Faculty Mannheim, University Heidelberg, Mannheim, 68167, Germany, DZHK (German Center for Cardiovascular Research), Partner Site, Heidelberg-Mannheim, Mannheim, Germany.
Abstract
BACKGROUND: The presence of any underlying heart condition could influence outcomes during the coronavirus disease 2019 (COVID-19). METHODS: The registry HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19, NCT04334291) is an international ambispective study, enrolling COVID-19 patients discharged from hospital, dead or alive. RESULTS: HOPE enrolled 2798 patients from 35 centers in 7 countries. Median age was 67 years (IQR: 53.0-78.0), and most were male (59.5%). A relevant heart disease was present in 682 (24%) cases. These were older, more frequently male, with higher overall burden of cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, smoking habit, obesity) and other comorbidities such renal failure, lung, cerebrovascular disease and oncologic antecedents (p < 0.01, for all). The heart cohort received more corticoids (28.9% vs. 20.4%, p < 0.001), antibiotics, but less hydroxychloroquine, antivirals or tocilizumab. Considering the epidemiologic profile, a previous heart condition was independently related with shortterm mortality in the Cox multivariate analysis (1.62; 95% CI 1.29-2.03; p < 0.001). Moreover, heart patients needed more respiratory, circulatory support, and presented more in-hospital events, such heart failure, renal failure, respiratory insufficiency, sepsis, systemic infammatory response syndrome and clinically relevant bleedings (all, p < 0.001), and mortality (39.7% vs. 15.5%; p < 0.001). CONCLUSIONS: An underlying heart disease is an adverse prognostic factor for patients suffering COVID-19. Its presence could be related with different clinical drug management and would benefit from maintaining treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers during in-hospital stay.
BACKGROUND: The presence of any underlying heart condition could influence outcomes during the coronavirus disease 2019 (COVID-19). METHODS: The registry HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19, NCT04334291) is an international ambispective study, enrolling COVID-19patients discharged from hospital, dead or alive. RESULTS: HOPE enrolled 2798 patients from 35 centers in 7 countries. Median age was 67 years (IQR: 53.0-78.0), and most were male (59.5%). A relevant heart disease was present in 682 (24%) cases. These were older, more frequently male, with higher overall burden of cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, smoking habit, obesity) and other comorbidities such renal failure, lung, cerebrovascular disease and oncologic antecedents (p < 0.01, for all). The heart cohort received more corticoids (28.9% vs. 20.4%, p < 0.001), antibiotics, but less hydroxychloroquine, antivirals or tocilizumab. Considering the epidemiologic profile, a previous heart condition was independently related with shortterm mortality in the Cox multivariate analysis (1.62; 95% CI 1.29-2.03; p < 0.001). Moreover, heart patients needed more respiratory, circulatory support, and presented more in-hospital events, such heart failure, renal failure, respiratory insufficiency, sepsis, systemic infammatory response syndrome and clinically relevant bleedings (all, p < 0.001), and mortality (39.7% vs. 15.5%; p < 0.001). CONCLUSIONS: An underlying heart disease is an adverse prognostic factor for patients suffering COVID-19. Its presence could be related with different clinical drug management and would benefit from maintaining treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers during in-hospital stay.
Authors: Elissa Driggin; Thomas M Maddox; Keith C Ferdinand; James N Kirkpatrick; Bonnie Ky; Alanna A Morris; J Brendan Mullen; Sahil A Parikh; Daniel M Philbin; Muthiah Vaduganathan Journal: J Am Coll Cardiol Date: 2021-02-12 Impact factor: 24.094
Authors: Maria-Luiza Luchian; Andreea Motoc; Stijn Lochy; Julien Magne; Dries Belsack; Johan De Mey; Bram Roosens; Karen Van den Bussche; Sven Boeckstaens; Hadischat Chameleva; Jolien Geers; Laura Houard; Tom De Potter; Sabine Allard; Caroline Weytjens; Steven Droogmans; Bernard Cosyns Journal: Diagnostics (Basel) Date: 2021-12-28
Authors: Maria-Luiza Luchian; Andreea Iulia Motoc; Stijn Lochy; Julien Magne; Bram Roosens; Dries Belsack; Karen Van den Bussche; Berlinde von Kemp; Xavier Galloo; Clara François; Esther Scheirlynck; Sven Boeckstaens; Tom De Potter; Lucie Seyler; Johan van Laethem; Sophie Hennebicq; Caroline Weytjens; Steven Droogmans; Bernard Cosyns Journal: Cardiol J Date: 2021-09-28 Impact factor: 2.737